Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Emily K. Makowski"'
Autor:
Emily K. Makowski, Hsin-Ting Chen, Tiexin Wang, Lina Wu, Jie Huang, Marissa Mock, Patrick Underhill, Emma Pelegri-O’Day, Erick Maglalang, Dwight Winters, Peter M. Tessier
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
ABSTRACTEarly identification of antibody candidates with drug-like properties is essential for simplifying the development of safe and effective antibody therapeutics. For subcutaneous administration, it is important to identify candidates with low s
Externí odkaz:
https://doaj.org/article/36271266403a4691a2dd72e35b369f74
Autor:
Jennifer M. Zupancic, Matthew D. Smith, Hanna Trzeciakiewicz, Mary E. Skinner, Sean P. Ferris, Emily K. Makowski, Michael J. Lucas, Nikki McArthur, Ravi S. Kane, Henry L. Paulson, Peter M. Tessier
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Single-domain antibodies, also known as nanobodies, are broadly important for studying the structure and conformational states of several classes of proteins, including membrane proteins, enzymes, and amyloidogenic proteins. Conformational nanobodies
Externí odkaz:
https://doaj.org/article/744b44e777364c28a6fe9024584e8b23
Autor:
Emily K. Makowski, Patrick C. Kinnunen, Jie Huang, Lina Wu, Matthew D. Smith, Tiexin Wang, Alec A. Desai, Craig N. Streu, Yulei Zhang, Jennifer M. Zupancic, John S. Schardt, Jennifer J. Linderman, Peter M. Tessier
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
Optimising antibody properties such as affinity can be detrimental to other key properties. Here the authors use machine learning to simplify the identification of antibodies with co-optimal levels of affinity and specificity for a clinical-stage ant
Externí odkaz:
https://doaj.org/article/0014043dced04499aebddc31d0764ef0
Autor:
Emily K. Makowski, Hongwei Chen, Matthew Lambert, Eric M. Bennett, Nicole S. Eschmann, Yulei Zhang, Jennifer M. Zupancic, Alec A. Desai, Matthew D. Smith, Wenjia Lou, Amendra Fernando, Timothy Tully, Christopher J. Gallo, Laura Lin, Peter M. Tessier
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Self-association governs the viscosity and solubility of therapeutic antibodies in high-concentration formulations used for subcutaneous delivery, yet it is difficult to reliably identify candidates with low self-association during antibody discovery
Externí odkaz:
https://doaj.org/article/b7a6b619288444029f50f9d427dbd60c
Autor:
John S. Schardt, Ghasidit Pornnoppadol, Alec A. Desai, Kyung Soo Park, Jennifer M. Zupancic, Emily K. Makowski, Matthew D. Smith, Hongwei Chen, Mayara Garcia de Mattos Barbosa, Marilia Cascalho, Thomas M. Lanigan, James J. Moon, Peter M. Tessier
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
Abstract Monoclonal antibodies that target SARS-CoV-2 with high affinity are valuable for a wide range of biomedical applications involving novel coronavirus disease (COVID-19) diagnosis, treatment, and prophylactic intervention. Strategies for the r
Externí odkaz:
https://doaj.org/article/75354dc4a1d54b489cf8d0e0fd26f7ef
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
There is intense and widespread interest in developing monoclonal antibodies as therapeutic agents to treat diverse human disorders. During early-stage antibody discovery, hundreds to thousands of lead candidates are identified, and those that lack o
Externí odkaz:
https://doaj.org/article/b6bd88b0a74649759d8be0f1d8599c36
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
The rapidly evolving nature of antibody drug development has resulted in technologies that generate vast numbers (hundreds to thousands) of lead antibody candidates during early discovery. These candidates must be rapidly pared down to identify the m
Externí odkaz:
https://doaj.org/article/1bd7a94122b74aef990a173a80328531
Publikováno v:
PLoS Computational Biology, Vol 18, Iss 5, p e1010160 (2022)
SARS-CoV-2 variants with enhanced transmissibility represent a serious threat to global health. Here we report machine learning models that can predict the impact of receptor-binding domain (RBD) mutations on receptor (ACE2) affinity, which is linked
Externí odkaz:
https://doaj.org/article/6c417fcc7db24638be21640e45224347
Publikováno v:
Curr Opin Biotechnol
Monoclonal antibodies are being used to treat a remarkable breadth of human disorders. Nevertheless, there are several key challenges at the earliest stages of antibody drug development that need to be addressed using simple and widely accessible met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfdcf48c16e3aafcebe5dd9fce54c2b4
https://doi.org/10.1016/j.copbio.2021.10.027
https://doi.org/10.1016/j.copbio.2021.10.027
Autor:
Priyanka Gupta, Emily K. Makowski, Sandeep Kumar, Yulei Zhang, Justin M. Scheer, Peter M. Tessier
Publikováno v:
Mol Pharm
The widespread interest in antibody therapeutics has led to much focus on identifying antibody candidates with favorable developability properties. In particular, there is broad interest in identifying antibody candidates with highly repulsive self-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06dc1959d39e5d412092dc4528b1bf0
https://doi.org/10.1021/acs.molpharmaceut.1c00373
https://doi.org/10.1021/acs.molpharmaceut.1c00373